2.12

6.19% -0.14

After Hours: 2.15 0.03 +1.42%

Nuvation Bio Inc (NUVB)

Overview News Price History Option Chain Discussions Forecast

Nuvation Bio Inc stock is traded at $2.12, with a volume of 4.77M. It is down -6.19% in the last 24 hours and down -2.75% over the past month. Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Previous Close:

$2.26

Open:

$2.24

24h Volume:

4.77M

Relative Volume:

1.41

Market Cap:

$719.23M

Revenue:

Net Income/Loss:

$-75.80M

P/E Ratio:

-6.0571

EPS:

-0.35

Net Cash Flow:

$-68.07M

1W Performance:

-7.83%

1M Performance:

-2.75%

6M Performance:

-26.90%

1Y Performance:

-29.10%

1-Day Range:

$2.11

$2.27

1-Week Range:

$2.11

$2.415

52-Week Range:

$1.54

$3.97

Nuvation Bio Inc Stock (NUVB) Company Profile

Name

Nuvation Bio Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

(415) 754-3517

Address

357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO

Employee

273

Twitter

Next Earnings Date

2025-03-05

Latest SEC Filings

NUVB's Discussions on Twitter

Compare NUVB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NUVB Nuvation Bio Inc	2.12	782.60M	0	-75.80M	-68.07M	-0.35
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-23-25	Initiated	Citizens JMP	Mkt Outperform
Mar-27-24	Upgrade	Jefferies	Hold → Buy
Mar-26-24	Upgrade	BTIG Research	Neutral → Buy
Jan-06-23	Downgrade	Jefferies	Buy → Hold
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
May-04-22	Initiated	H.C. Wainwright	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Apr-06-21	Initiated	RBC Capital Mkts	Outperform
Mar-08-21	Initiated	BMO Capital Markets	Outperform
Mar-08-21	Initiated	BTIG Research	Buy
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	Jefferies	Buy
Mar-08-21	Initiated	Wedbush	Outperform

View All

Nuvation Bio Inc Stock (NUVB) Latest News

04:11 AM

Deutsche Bank AG Increases Stock Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

04:11 AM

May 30, 2025

Citizens JMP highlights key ASCO presentations - Investing.com

May 30, 2025

Citizens JMP highlights key ASCO presentations By Investing.com - Investing.com UK

May 30, 2025

May 29, 2025

D. E. Shaw & Co. Inc. Sells 63,827 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World

May 29, 2025

May 28, 2025

Nuvation Bio Inc. (NYSE:NUVB) Shares Acquired by Millennium Management LLC - Defense World

May 28, 2025

May 23, 2025

Nuvation Bio Inc. Ratifies the Appointment of KPMG LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025 - marketscreener.com

May 23, 2025

Nuvation Bio Holds Successful Annual Meeting 2025 - TipRanks

May 23, 2025

Nuvation Bio stockholders approve board members and executive pay - Investing.com

May 23, 2025

Nuvation Bio’s SWOT analysis: taletrectinib approval could transform stock outlook - Investing.com Australia

May 23, 2025

May 22, 2025

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting - BioSpace

May 22, 2025

May 21, 2025

Northern Trust Corp Acquires 563,627 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World

May 21, 2025

Brokerages Set Nuvation Bio Inc. (NYSE:NUVB) Target Price at $7.83 - Defense World

May 21, 2025

May 17, 2025

Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way? - simplywall.st

May 17, 2025

Wedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB) - Defense World

May 17, 2025

May 16, 2025

Nuvation Bio (NUVB) Maintains Outperform Rating by Wedbush | NUV - GuruFocus

May 16, 2025

Nuvation Bio (NUVB) Maintains Outperform Rating by Wedbush | NUVB Stock News - GuruFocus

May 16, 2025

May 14, 2025

Dimensional Fund Advisors LP Cuts Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

May 14, 2025

May 13, 2025

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025 - BioSpace

May 13, 2025

Breakthrough Comparison: How Nuvation's Cancer Drug Stacks Up Against Entrectinib in Crucial Lung Cancer Study - Stock Titan

May 13, 2025

Nuvation Bio Inc. (NYSE:NUVB) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025

Nuvation Bio Inc. (NYSE:NUVB) Shares Bought by Price T Rowe Associates Inc. MD - Defense World

May 13, 2025

Nuvation Bio to Participate in Upcoming May 2025 Investor Conferences - BioSpace

May 13, 2025

May 12, 2025

Nuvation Bio’s Positive Outlook: Taletrectinib Approval and Financial Strength - TipRanks

May 12, 2025